肺癌发病率，2019-2020 年，美国：COVID-19 大流行的潜在影响

IF 3.3 3区医学 Q1 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

Annals of Epidemiology Pub Date : 2024-08-26 DOI:10.1016/j.annepidem.2024.08.005

Christine M. Kava , David A. Siegel , Susan A. Sabatino , Jin Qin , Thomas B. Richards , S. Jane Henley

{"title":"肺癌发病率，2019-2020 年，美国：COVID-19 大流行的潜在影响","authors":"Christine M. Kava , David A. Siegel , Susan A. Sabatino , Jin Qin , Thomas B. Richards , S. Jane Henley","doi":"10.1016/j.annepidem.2024.08.005","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>Cancer incidence declined during the COVID-19 pandemic in part due to health care delivery challenges. We examined the impact of the COVID-19 pandemic on changes in lung cancer incidence.</p></div><div><h3>Methods</h3><p>We used 2019–2020 US Cancer Statistics data from 49 cancer registries covering 97 % of the US population. We calculated the number of new lung cancer diagnoses in 2019 and 2020, age-adjusted lung cancer incidence rates per 100,000 persons, and 2019-to-2020 % changes in incidence rates. We also calculated number and percentage of new lung cancer diagnoses by month and stage at diagnosis.</p></div><div><h3>Results</h3><p>The age-adjusted lung cancer incidence rate per 100,000 persons was 47.9 in 2019 vs. 41.4 in 2020—a 13.6 % decrease. Differences in the percentage change in incidence rates were observed by age, race and ethnicity, US census region, histology, and stage at diagnosis. A higher percentage of people were diagnosed at distant stage in 2020 than 2019.</p></div><div><h3>Conclusions</h3><p>This report provides new insight into subgroups that experienced the greatest decline in observed lung cancer incidence during the first year of the COVID-19 pandemic. The findings can be used to inform intervention efforts to improve lung cancer screening, diagnosis, and treatment.</p></div>","PeriodicalId":50767,"journal":{"name":"Annals of Epidemiology","volume":"98 ","pages":"Pages 44-50"},"PeriodicalIF":3.3000,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Lung cancer incidence, 2019–2020, United States: The potential impact of the COVID-19 pandemic\",\"authors\":\"Christine M. Kava , David A. Siegel , Susan A. Sabatino , Jin Qin , Thomas B. Richards , S. Jane Henley\",\"doi\":\"10.1016/j.annepidem.2024.08.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><p>Cancer incidence declined during the COVID-19 pandemic in part due to health care delivery challenges. We examined the impact of the COVID-19 pandemic on changes in lung cancer incidence.</p></div><div><h3>Methods</h3><p>We used 2019–2020 US Cancer Statistics data from 49 cancer registries covering 97 % of the US population. We calculated the number of new lung cancer diagnoses in 2019 and 2020, age-adjusted lung cancer incidence rates per 100,000 persons, and 2019-to-2020 % changes in incidence rates. We also calculated number and percentage of new lung cancer diagnoses by month and stage at diagnosis.</p></div><div><h3>Results</h3><p>The age-adjusted lung cancer incidence rate per 100,000 persons was 47.9 in 2019 vs. 41.4 in 2020—a 13.6 % decrease. Differences in the percentage change in incidence rates were observed by age, race and ethnicity, US census region, histology, and stage at diagnosis. A higher percentage of people were diagnosed at distant stage in 2020 than 2019.</p></div><div><h3>Conclusions</h3><p>This report provides new insight into subgroups that experienced the greatest decline in observed lung cancer incidence during the first year of the COVID-19 pandemic. The findings can be used to inform intervention efforts to improve lung cancer screening, diagnosis, and treatment.</p></div>\",\"PeriodicalId\":50767,\"journal\":{\"name\":\"Annals of Epidemiology\",\"volume\":\"98 \",\"pages\":\"Pages 44-50\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2024-08-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Epidemiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1047279724002163\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Epidemiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1047279724002163","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

摘要

目的在 COVID-19 大流行期间，癌症发病率有所下降，部分原因是医疗保健服务面临挑战。我们研究了 COVID-19 大流行对肺癌发病率变化的影响。方法我们使用了来自 49 个癌症登记处的 2019-2020 年美国癌症统计数据，这些数据覆盖了 97% 的美国人口。我们计算了 2019 年和 2020 年新诊断出的肺癌人数、每 10 万人中经年龄调整后的肺癌发病率以及 2019-2020 年发病率的百分比变化。我们还计算了按月份和诊断分期分列的新诊断肺癌人数和百分比。结果2019 年每 10 万人中年龄调整后的肺癌发病率为 47.9 例，2020 年为 41.4 例，下降了 13.6%。不同年龄、种族和民族、美国人口普查地区、组织学和诊断阶段的发病率百分比变化存在差异。与 2019 年相比，2020 年被诊断为远期分期的人数比例更高。结论本报告提供了关于 COVID-19 大流行第一年肺癌发病率下降幅度最大的亚组的新见解。这些发现可为改善肺癌筛查、诊断和治疗的干预工作提供参考。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Lung cancer incidence, 2019–2020, United States: The potential impact of the COVID-19 pandemic

Purpose

Cancer incidence declined during the COVID-19 pandemic in part due to health care delivery challenges. We examined the impact of the COVID-19 pandemic on changes in lung cancer incidence.

Methods

We used 2019–2020 US Cancer Statistics data from 49 cancer registries covering 97 % of the US population. We calculated the number of new lung cancer diagnoses in 2019 and 2020, age-adjusted lung cancer incidence rates per 100,000 persons, and 2019-to-2020 % changes in incidence rates. We also calculated number and percentage of new lung cancer diagnoses by month and stage at diagnosis.

Results

The age-adjusted lung cancer incidence rate per 100,000 persons was 47.9 in 2019 vs. 41.4 in 2020—a 13.6 % decrease. Differences in the percentage change in incidence rates were observed by age, race and ethnicity, US census region, histology, and stage at diagnosis. A higher percentage of people were diagnosed at distant stage in 2020 than 2019.

Conclusions

This report provides new insight into subgroups that experienced the greatest decline in observed lung cancer incidence during the first year of the COVID-19 pandemic. The findings can be used to inform intervention efforts to improve lung cancer screening, diagnosis, and treatment.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Annals of Epidemiology 医学-公共卫生、环境卫生与职业卫生

CiteScore

7.40

自引率

1.80%

发文量

207

审稿时长

59 days

期刊介绍： The journal emphasizes the application of epidemiologic methods to issues that affect the distribution and determinants of human illness in diverse contexts. Its primary focus is on chronic and acute conditions of diverse etiologies and of major importance to clinical medicine, public health, and health care delivery.